About us

Longevience AB

Longevience AB is a subsidiary of Milmed Unico AB focusing on research and marketing of its unique longevity product, AgeViva. During the last two years, our research progress emerging from our team at the Sapienza University, Rome, has focused upon the longevity area. The results have been remarkably promising and have shown that AgeViva has a positive effect on several important hallmarks of ageing.
Among these indications, by supporting mitochondrial and cellular function, it holds the potential to add more healthy, active years to lives of the aged. With AgeViva, we aim to facilitate the maintenance of vitality and independence among more individuals as they age.

Longevience AB is a subsidiary of Milmed Unico AB focusing on research and marketing of its unique longevity product, AgeViva.

The history of AgeViva-Milmed

Research into the positive impact of electromagnetic millimeter waves on biological objects had been continuing for many decades. It has mainly concerned influencing the biosubstrate from the outside, our pharmabiotic, (LBP-Live Biotherapeutic Products), treats from the inside.

A major step forward was taken when a suspension containing treated yeast cells was developed. Although the manufacturing process was complicated and the shelf life very limited, it provided great opportunities for fact-finding research. The suspension was named Milmed, and the unique properties of the product originated from the electromagnetic millimeter wavelength-treated strain of yeast cells.
Case studies began in 2007 but the real work started when Professor Trevor Archer joined the existing team. He led 7 in vivo studies within a Parkinson’s model between the years 2008-2013 at Uppsala University.

The results of these studies formed the basis for the first patent application in the product's history, a patent for the treatment of neurodegenerative diseases that was approved back in 2011.
Research in the form of preclinical trials continued at a steady pace to further to strengthen the product's legitimacy. Another imperative step was taken when a collaboration with Europe's largest university in Sapienza, Rome, began in 2016. Professor Rita Businaro is still, at present, leading our research work regarding in vitro studies. The primary priority at the Sapienza was toxicity studies to prove that our product is completely free of toxins. This was carried out in 2017 and it turned out that AgeViva does not induce any toxicity at all. The product's non-toxicity has been proven repeatedly by in vitro and in vivo studies and through ingestion by over 1500 individuals.

Several human studies were conducted after we discovered clear indications that our yeast product relieves or removes allergic symptoms. In these studies, the focus was primarily set on pollen, grass and fur allergies. The results were very satisfying, and a subsequent patent application was approved in October 2020.
An extended research agreement with Sapienza University was signed in April 2019 where indications of a new treatment area, inflammatory diseases, was studied.

The positive results of these studies led the company to apply for a new patent, filed in June 2021. The company received an approval for treatment of inflammatory diseases in September of 2022. The work continues towards becoming an approved medicinal pharmabiotic and synopsis for future clinical trials is ready.

An important priority has been the capacity to produce the probiotic in a dry form.

This process was initiated in 2014 and after several years of research and testing of the dry product, it was finalized in collaboration with Sapienza University and Orkla Group in April 2021. This is crucial for future development and the possibility to take the product to market. AgeViva is now a stand-alone pharmabiotic product and the product has already changed many ‘AgeViva-users’ lives in a positive direction.
Targeting the Biology of Ageing

AgeViva supports mitochondrial function, reduces oxidative stress, and promotes healthy immune regulation. Together, these actions aim to preserve homeostasis—the body’s capacity to keep internal systems in balance despite ageing and external stress.
About us
Research
News
Contact
Longevience AB
Org.nr:559500-0778
info@longevience.com
© 2025 LongeVience. All rights reserved.
A Focus on Healthspan, Not Lifespan
pedesign-logo-clean